Cubist Systematic Strategies LLC Sells 167,321 Shares of Cryoport, Inc. (NASDAQ:CYRX)

Cubist Systematic Strategies LLC lessened its holdings in Cryoport, Inc. (NASDAQ:CYRX - Free Report) by 60.8% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 108,037 shares of the company's stock after selling 167,321 shares during the period. Cubist Systematic Strategies LLC owned 0.22% of Cryoport worth $841,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in CYRX. Barclays PLC raised its position in Cryoport by 272.9% during the third quarter. Barclays PLC now owns 81,417 shares of the company's stock valued at $660,000 after purchasing an additional 59,582 shares in the last quarter. SG Americas Securities LLC raised its position in Cryoport by 44.8% during the fourth quarter. SG Americas Securities LLC now owns 146,789 shares of the company's stock valued at $1,142,000 after purchasing an additional 45,430 shares in the last quarter. Rhumbline Advisers raised its position in Cryoport by 2.9% during the fourth quarter. Rhumbline Advisers now owns 63,284 shares of the company's stock valued at $492,000 after purchasing an additional 1,764 shares in the last quarter. JPMorgan Chase & Co. raised its position in Cryoport by 1,464.4% during the third quarter. JPMorgan Chase & Co. now owns 305,237 shares of the company's stock valued at $2,475,000 after purchasing an additional 285,726 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its position in Cryoport by 8.9% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 60,003 shares of the company's stock valued at $467,000 after purchasing an additional 4,902 shares in the last quarter. Hedge funds and other institutional investors own 92.90% of the company's stock.

Cryoport Stock Performance

Cryoport stock remained flat at $6.58 during trading hours on Tuesday. The company's stock had a trading volume of 26,807 shares, compared to its average volume of 541,309. The business's 50 day moving average price is $5.94 and its 200-day moving average price is $6.85. The company has a current ratio of 5.70, a quick ratio of 5.32 and a debt-to-equity ratio of 0.48. The stock has a market capitalization of $329.90 million, a P/E ratio of -1.95 and a beta of 1.92. Cryoport, Inc. has a fifty-two week low of $4.58 and a fifty-two week high of $12.58.

Cryoport (NASDAQ:CYRX - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.01. Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%. The business had revenue of $41.04 million for the quarter, compared to analysts' expectations of $56.19 million. On average, sell-side analysts expect that Cryoport, Inc. will post -0.99 earnings per share for the current fiscal year.

Insider Transactions at Cryoport

In other news, CEO Jerrell Shelton sold 4,620 shares of the business's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $6.29, for a total value of $29,059.80. Following the sale, the chief executive officer now directly owns 765,399 shares of the company's stock, valued at $4,814,359.71. The trade was a 0.60% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders have sold a total of 19,830 shares of company stock valued at $118,353 in the last ninety days. 10.00% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on CYRX shares. Morgan Stanley lowered their price target on Cryoport from $8.00 to $7.00 and set an "equal weight" rating on the stock in a research report on Monday, May 5th. Needham & Company LLC reiterated a "buy" rating and issued a $11.00 price objective on shares of Cryoport in a report on Thursday, May 8th. UBS Group lifted their price objective on Cryoport from $10.00 to $11.00 and gave the stock a "buy" rating in a report on Tuesday, April 1st. Roth Mkm reiterated a "buy" rating and issued a $15.00 price objective on shares of Cryoport in a report on Tuesday, April 1st. Finally, Guggenheim reiterated a "buy" rating and issued a $10.00 price objective on shares of Cryoport in a report on Wednesday, April 16th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat.com, Cryoport presently has an average rating of "Moderate Buy" and an average target price of $11.00.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.